Improving Radiation Therapy For Pancreatic Cancer

改善胰腺癌的放射治疗

基本信息

  • 批准号:
    8880445
  • 负责人:
  • 金额:
    $ 18.6万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2015
  • 资助国家:
    美国
  • 起止时间:
    2015-04-01 至 2017-03-31
  • 项目状态:
    已结题

项目摘要

 DESCRIPTION (provided by applicant): Radiation therapy plays a key role in pancreatic ductal adenocarcinoma (PDAC) treatment. However, it faces challenges from the fact that pancreatic cancer stem cells (PCSC) are resistant to ionizing radiation. Moreover, a recent finding indicates that radiation can reprogram nonstem- cancer cells into cancer stem cells, which is in agreement with our finding, namely iPCSC. Compelling evidence show that PDAC cells in expressing elevated levels of aldehyde dehydrogenase 1 (ALDH1), ALDHbrightcells, are PCSC/iPCSC. In the past, we demonstrated that cytotoxic T cells (CTL) specifically recognizing an epitope from the ALDH1A1 isoform eliminate ALDHbright cells in vitro and in vivo. However, the clinical applicability of adoptive T cell-based immunotherapy is limited by HLA class I restriction and requires ex vivo expansion of autologous or allogeneic T cells using a variety of methodologies. To overcome the limitations of CTL-targeting of ALDHbright cells, we tested the novel approach of using disulfiram (DSF) to target PCSC. DSF is a dithiocarbamate and an FDA-approve inhibitor of ALDH for treatment of alcoholism. Its toxicity to PDAC cells has been shown to be enhanced by the binding of the essential trace element copper (Cu++) to form DSF/Cu complexes. We found recently using PDAC cell lines that: i) PCSC increased two days after in vitro fractionated irradiation; ii) DSF/Cu depleted PCSC during the treatment gap, and abolished in vitro sphere formation of irradiated cells; iii) DSF/Cu downregulated Wnt pathway, a key cancer stem cell pathway, in irradiated PDAC cells, and iv) DSF/Cu blocked radiation induced re-expressing mRNA of stemness genes. These findings provide the rationale for our central hypothesis that DSF/Cu depletes pre-existing PCSC and radiation-induced PCSC which results in significant increases in the efficacy of radiation therapy. In Aim1, we will determine that DSF/Cu eliminates both PCSC and iPCSC in vitro and in vivo. In Aim2, we will examine that RT combined with DSF/Cu can effectively eliminate stem- and nonstem- PDAC cells in a neoadjuvant setting using xeno- and syngeneic- pancreatic tumors in mice. In Aim3, we will compare the efficacy of combination of DSF/Cu, RT and 5-Fluorouracil (5-FU), a commonly used radiosensitizer for PDAC vs conventional chemoradiation consisting of RT and 5-FU in a neoadjuvant setting in xeno- and syngeneic- PDAC mouse model systems . At the conclusion of the proposed studies, we will have evaluated DSF/Cu as a cytotoxic agent of pre-existing PSCS/iPSCS and as a blocker of generation of iPCSC, obtained knowledge of the mechanism(s) by which DSF/Cu enhances efficacy of radiation and chemoradiation therapy, and formed the foundation of a novel neoadjuvant therapy for improved efficacy of radiation and chemoradiation by combination with a FDA approved drug DSF and a nutrition supplement Copper gluconate.
 描述(申请人提供):放射治疗在胰腺导管腺癌(PDAC)的治疗中起着关键作用。然而,由于胰腺癌干细胞(PCSC)对电离辐射具有抵抗力,它面临着挑战。此外,最近的一项发现表明,辐射可以将非干细胞癌细胞重新编程为癌症干细胞,这与我们的发现一致,即IPCSC。令人信服的证据表明,表达高水平乙醛脱氢酶1(ALDH1)的PDAC细胞是PCSC/IPCSC。在过去,我们证明了细胞毒性T细胞(CTL)在体外和体内都能特异性识别ALDH1A1亚型的表位,从而消除ALDHbright细胞。然而,过继T细胞免疫治疗的临床适用性受到HLAI类限制,需要使用各种方法体外扩增自体或同种异体T细胞。为了克服CTL靶向ALDHbright细胞的局限性,我们测试了使用双硫兰(DSF)靶向PCSC的新方法。DSF是一种二硫代氨基甲酸酯,是FDA批准的ALDH抑制剂,用于治疗酒精中毒。它对PDAC细胞的毒性是通过与必需的微量元素铜(Cu++)结合形成DSF/Cu络合物而增强的。我们最近利用PDAC细胞株发现:i)PCSC在体外分次照射后两天增加;ii)DSF/Cu在治疗间隙期间耗尽PCSC,并在体外取消受照射细胞的球体形成;iii)DSF/Cu下调受照射的PDAC细胞中关键的肿瘤干细胞途径Wnt途径,以及iv)DSF/Cu阻断辐射诱导的干细胞干基因的重新表达。这些发现为我们的中心假设提供了理论基础,即DSF/Cu耗尽了先前存在的PCSC和辐射诱导的PCSC,从而导致放射治疗疗效的显着提高。在AIM1中,我们将确定DSF/Cu在体外和体内都能消除PCSC和IPCSC。在AIM2中,我们将检验RT联合DSF/Cu在新的佐剂环境中使用异种和同基因胰腺肿瘤可以有效地消除干细胞和非干细胞PDAC细胞。在AIM3中,我们将在异种和同基因-PDAC小鼠模型系统中比较DSF/Cu、RT和5-FU(5-FU)的组合与传统的由RT和5-FU组成的新辅助放化疗的疗效。在拟议的研究结束时,我们将评估DSF/Cu作为既有PSCs/IPSCs的细胞毒剂和IPCSC生成的阻滞剂,了解DSF/Cu提高放化疗疗效的机制(S),并结合FDA批准的药物DSF和营养补充剂葡萄糖酸铜,为提高放化疗疗效的新型新辅助疗法奠定基础。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Xinhui Wang其他文献

Xinhui Wang的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Xinhui Wang', 18)}}的其他基金

Prevention of post-therapy breast cancer metastasis
预防乳腺癌治疗后转移
  • 批准号:
    10380153
  • 财政年份:
    2019
  • 资助金额:
    $ 18.6万
  • 项目类别:
Prevention of post-therapy breast cancer metastasis
预防乳腺癌治疗后转移
  • 批准号:
    9914094
  • 财政年份:
    2019
  • 资助金额:
    $ 18.6万
  • 项目类别:
Prevention of post-therapy breast cancer metastasis
预防乳腺癌治疗后转移
  • 批准号:
    10606639
  • 财政年份:
    2019
  • 资助金额:
    $ 18.6万
  • 项目类别:
T cell plasticity, fusion proteins and CAR T cell-based immunotherapy of head and neck cancer
T细胞可塑性、融合蛋白和基于CAR T细胞的头颈癌免疫疗法
  • 批准号:
    10455452
  • 财政年份:
    2018
  • 资助金额:
    $ 18.6万
  • 项目类别:
Improving Radiation Therapy For Pancreatic Cancer
改善胰腺癌的放射治疗
  • 批准号:
    9037627
  • 财政年份:
    2015
  • 资助金额:
    $ 18.6万
  • 项目类别:
B7-H3 in prognosis and immunotherapy of pancreatic cancer
B7-H3 在胰腺癌的预后和免疫治疗中的作用
  • 批准号:
    7877983
  • 财政年份:
    2009
  • 资助金额:
    $ 18.6万
  • 项目类别:
B7-H3 in prognosis and immunotherapy of pancreatic cancer
B7-H3 在胰腺癌的预后和免疫治疗中的作用
  • 批准号:
    7707605
  • 财政年份:
    2009
  • 资助金额:
    $ 18.6万
  • 项目类别:
B7-H3 in prognosis and immunotherapy of pancreatic cancer
B7-H3 在胰腺癌的预后和免疫治疗中的作用
  • 批准号:
    8719680
  • 财政年份:
    2009
  • 资助金额:
    $ 18.6万
  • 项目类别:

相似海外基金

Assessing The Impact of Heparanase and NDST2 Expression on Non-Small Cell Lung Adenocarcinoma Cell Motility
评估乙酰肝素酶和 NDST2 表达对非小细胞肺腺癌细胞运动的影响
  • 批准号:
    449570
  • 财政年份:
    2020
  • 资助金额:
    $ 18.6万
  • 项目类别:
    Studentship Programs
Analysis of cancer metastasis and invasion mechanism using a new lung adenocarcinoma cell line.
使用新的肺​​腺癌细胞系分析癌症转移和侵袭机制。
  • 批准号:
    16K10689
  • 财政年份:
    2016
  • 资助金额:
    $ 18.6万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Acquisition strategy of tumor-specific markers using established micropapillary pattern pulmonary adenocarcinoma cell line
使用已建立的微乳头模式肺腺癌细胞系获取肿瘤特异性标志物的策略
  • 批准号:
    26460441
  • 财政年份:
    2014
  • 资助金额:
    $ 18.6万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
The antibetic drug metformin inhibits esophageal adenocarcinoma cell proliferation in vitro and in vivo.
抗生素药物二甲双胍在体外和体内抑制食管腺癌细胞增殖。
  • 批准号:
    25860540
  • 财政年份:
    2013
  • 资助金额:
    $ 18.6万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
The cell permeable peptide inhibits pancreatic ductal adenocarcinoma cell proliferations and can be used as the molecular targeting dru
细胞通透肽抑制胰腺导管腺癌细胞增殖,可作为分子靶向药物
  • 批准号:
    25461969
  • 财政年份:
    2013
  • 资助金额:
    $ 18.6万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Basic Research for elucidation of chemo-resistance in mucinous adenocarcinoma cell.
阐明粘液腺癌细胞化疗耐药性的基础研究。
  • 批准号:
    22791532
  • 财政年份:
    2010
  • 资助金额:
    $ 18.6万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
TAS::75 0849::TAS IN THIS PHASE I SBIR THE BREAST CANCER ADENOCARCINOMA CELL LI
TAS::75 0849::TAS 在这一阶段 I SBIR 乳腺癌腺癌细胞 LI
  • 批准号:
    8164743
  • 财政年份:
    2010
  • 资助金额:
    $ 18.6万
  • 项目类别:
Role of Endothelin-1 in osteoblastic bone metastasis produced by a human lung adenocarcinoma cell line
Endothelin-1 在人肺腺癌细胞系产生的成骨细胞骨转移中的作用
  • 批准号:
    19790127
  • 财政年份:
    2007
  • 资助金额:
    $ 18.6万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
CONNEXIN 43 EXPRESSION IN ADENOCARCINOMA CELL LINE
连接蛋白 43 在腺癌细胞系中的表达
  • 批准号:
    6972483
  • 财政年份:
    2004
  • 资助金额:
    $ 18.6万
  • 项目类别:
The mechanisms of highly metastetic capasity in highly metastatic subpopulations of lung adenocarcinoma cell line and these clinical applications
肺腺癌细胞系高转移亚群的高转移能力机制及临床应用
  • 批准号:
    15590831
  • 财政年份:
    2003
  • 资助金额:
    $ 18.6万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了